Previous 10 | Next 10 |
— Enrollment for healthy volunteer QT study ongoing, topline data on schedule for Q4 2019 readout — — Company remains on track to resubmit NDA for oliceridine in Q1 2020 — — Cash runway as of June 30, 2019 continues to sufficiently fund...
The attack on opioids is intensifying once again, and the circle of companies falling victim is widening. On Aug. 1, Reuters reported that the State of Oklahoma is now making its final efforts to hold Johnson & Johnson (JNJ) responsible. The Trump Administration has decided to restrict a...
CHESTERBROOK, Pa., July 31, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced that it will release its financial ...
NEW ORLEANS , July 19, 2019 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Trevena, Inc. (NasdaqGS: TRVN). On...
Trevena ( TRVN +3% ) announced the appointment of Barry Shin as Chief Financial Officer. More news on: Trevena, Inc., Read more ...
CHESTERBROOK, Pa., June 27, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced the appointment of Barry Shin as Chie...
CHESTERBROOK, Pa., June 24, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced publication of APOLLO-2 (pivotal Ph...
Guardion Health Sciences (NASDAQ: GHSI ) +35% on receiving a patent from the European Union for its proprietary medical device, the MapcatSF. More news on: Guardion Health Sciences, Inc., DiaMedica Therapeutics Inc., Melinta Therapeutics, Inc., Stocks on the move, Read more .....
Trevena (NASDAQ: TRVN ) has initiated the healthy volunteer QT interval study for oliceridine, an investigational drug candidate for the management of moderate to severe acute pain. More news on: Trevena, Inc., Healthcare stocks news, Stocks on the move, Read more ...
CHESTERBROOK, Pa., June 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System conditions, ...
News, Short Squeeze, Breakout and More Instantly...
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK study with optimized formulation of TRV045 advances, with data expected 2H 2024 CHESTERBROOK, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- ...
2024-04-02 07:15:05 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for TRVN on April 2, 2024 05:40AM ET. The previous analyst recommendation was Market Outperform. TRVN was trading at $0.4 at issue of the analyst recommendation. Historical Analyst Re...
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 01, 2024 (GL...